Management under the New Management Concept “EIKEN ROAD MAP 2009”
First written in FY2016. 24 of 33 entries say "Restated". Latest entry: 2026-07-30.
The whole theme swung hardest in 2020: 2 of 11 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- 2026-07-30RestatedEarnings
「Against this backdrop, based on Management Plan 2030, the Group is pursuing priority measures centred on three focused business areas: “contributing to cancer prevention and treatment,” “contributing to the eradication and control of infectious diseases,” and “providing products and services useful in healthcare,” while undertaking fundamental reforms throughout the Group to strengthen its earnings base.」
The company continues to pursue Management Plan 2030, its three focused business areas and fundamental reforms to strengthen its earnings base. - FY2026ReframedAnnual report
「To respond to changes in the business environment and incorporate a sustainability management perspective, the Group has established “EIKEN Vision 2030” as its vision for 2030.」
The Group reviewed the former “EIKEN ROAD MAP 2030” and reorganized its vision for 2030 as “EIKEN Vision 2030.” It has also formulated a five-year management plan with the fiscal year ending March 2027 as its first year and the fiscal year ending March 2031 as its final year. - FY2026-H1RestatedAnnual report
「Under these business conditions, the Group has adopted “Challenges to Innovation” as the slogan of the medium-term management plan formulated based on the management vision “EIKEN ROAD MAP 2030.” It will implement priority measures centered on three focus business areas—contributing to cancer prevention and treatment, contributing to the eradication and control of infectious diseases, and providing products and services that support healthcare—while pursuing fundamental transformation across the Group to strengthen its earnings base.」
The Group continues to pursue EIKEN ROAD MAP 2030, the “Challenges to Innovation” slogan of the new medium-term management plan, the three focus business areas and fundamental transformation of its earnings base. - FY2025AdvancedAnnual report
「Under the new medium-term management plan beginning in April 2025 and covering the fiscal years ending March 2026 through March 2028, the Group has adopted “Challenges to Innovation” as its slogan and will pursue fundamental transformation to strengthen its earnings base.」
Under EIKEN ROAD MAP 2030, the Group launched a new medium-term management plan with the slogan “Challenges to Innovation” and set out fundamental transformation of its earnings base. - FY2024-Q1RestatedAnnual report
「Under these business conditions, the Group is implementing priority measures centered on three focus business areas in line with the medium-term management plan formulated based on the management vision “EIKEN ROAD MAP 2030”: contributing to cancer prevention and treatment, contributing to the eradication and control of infectious diseases, and providing products and services that support healthcare. Across the Group, it is working to achieve sustainable growth and steady improvement in profitability.」
The Group continues to pursue a policy of implementing priority measures centered on three focus business areas based on EIKEN ROAD MAP 2030 and the medium-term management plan. - FY2023-Q3RestatedAnnual report
「Under these business conditions, the Group is implementing priority measures centered on three focus business areas in line with the medium-term management plan formulated based on the management vision “EIKEN ROAD MAP 2030”: contributing to cancer prevention and treatment, contributing to the eradication and control of infectious diseases, and providing products and services that support healthcare. Across the Group, it is working to achieve sustainable growth and steady improvement in profitability.」
The Group continues to implement priority measures centered on three focus business areas based on EIKEN ROAD MAP 2030 and the medium-term management plan. - FY2023-Q2RestatedAnnual report
「Under these business conditions, the Group is implementing priority measures centered on three focus business areas in line with the medium-term management plan formulated based on the management vision “EIKEN ROAD MAP 2030”: contributing to cancer prevention and treatment, contributing to the eradication and control of infectious diseases, and providing products and services that support healthcare. Across the Group, it is working to achieve sustainable growth and steady improvement in profitability.」
The Group continues to pursue a policy of implementing priority measures centered on three focus business areas—cancer, infectious diseases and healthcare—based on EIKEN ROAD MAP 2030 and the medium-term management plan. - FY2023-Q1RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the management vision “EIKEN ROAD MAP 2030” and is implementing priority measures centered on three focus business areas: contributing to cancer prevention and treatment, contributing to the eradication and control of infectious diseases, and providing products and services that support healthcare. Across the Group, it is working to achieve sustainable growth and steady improvement in profitability.」
The Group continues to pursue a medium-term management plan based on EIKEN ROAD MAP 2030 and priority measures centered on three focus business areas. - FY2022ReframedAnnual report
「To respond to changes in the business environment and incorporate a sustainability management perspective, the Group reviewed its management vision “EIKEN ROAD MAP 2019” and redefined it as “EIKEN ROAD MAP 2030,” with 2030 as the target year.」
The Group reviewed EIKEN ROAD MAP 2019 and redefined it as EIKEN ROAD MAP 2030, with 2030 as the target year. It also adopted “Beyond the Field ~ Team × Challenge ~” as its new slogan. - FY2022-Q3RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the management vision “EIKEN ROAD MAP 2019.” It is working across the Group to achieve sustainable growth and improve profitability, with four priority measures: developing the foundations needed to improve management efficiency, promoting global expansion, maintaining domestic sales and increasing market share, and strengthening research and development capabilities. It also aims to contribute to measures against the disease through the stable supply of reagents for detecting the novel coronavirus in Japan and their global expansion.」
The Group continues to pursue a medium-term management plan based on EIKEN ROAD MAP 2019, the four priority measures and contributions to measures against infectious diseases through reagents for detecting the novel coronavirus. - FY2022-Q2RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the management vision “EIKEN ROAD MAP 2019.” It is working across the Group to achieve sustainable growth and improve profitability, with four priority measures: developing the foundations needed to improve management efficiency, promoting global expansion, maintaining domestic sales and increasing market share, and strengthening research and development capabilities. It also aims to contribute to measures against the disease through the stable supply of reagents for detecting the novel coronavirus in Japan and their global expansion.」
The Group continues to pursue the four priority measures based on EIKEN ROAD MAP 2019 and contribute to measures against infectious diseases through the stable domestic supply and global expansion of reagents for detecting the novel coronavirus. - FY2022-Q1RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the management vision “EIKEN ROAD MAP 2019.” It is working across the Group to achieve sustainable growth and improve profitability, with four priority measures: developing the foundations needed to improve management efficiency, promoting global expansion, maintaining domestic sales and increasing market share, and strengthening research and development capabilities. It also aims to contribute to measures against the disease through the stable supply of reagents for detecting the novel coronavirus in Japan and their global expansion.」
The Group continues to pursue the four priority measures based on EIKEN ROAD MAP 2019, with an additional commitment to contributing to measures against infectious diseases through the stable domestic supply and global expansion of reagents for detecting the novel coronavirus. - FY2021-Q2RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the basic strategies of the management vision “EIKEN ROAD MAP2019.” It is working across the Group to achieve sustainable growth and improve profitability, with four priority measures: developing the foundations needed to improve management efficiency, promoting global expansion, maintaining domestic sales and increasing market share, and strengthening research and development capabilities. It also aims to contribute to measures against the disease by supplying reagents for detecting the novel coronavirus.」
The Group continues to pursue the four priority measures based on EIKEN ROAD MAP2019, with an additional commitment to contributing to measures against infectious diseases through the supply of reagents for detecting the novel coronavirus. - FY2020RestatedAnnual report
「In April 2019, the Group formulated the management vision “EIKEN ROAD MAP 2019.” Over the 10 years through fiscal 2028, the 90th anniversary of its founding, the Group is pursuing the realization of its grand vision, “Saving Your Health (As a global clinical diagnostics company, continuing to protect people’s health).” Based on the following basic strategies, it formulated and is implementing a medium-term management plan covering the fiscal years ending March 2020 through March 2022.」
The Group continues to pursue EIKEN ROAD MAP 2019, the grand vision for fiscal 2028 and the medium-term management plan covering the fiscal years ending March 2020 through March 2022. - FY2020-Q2RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the basic strategies of the new management vision “EIKEN ROAD MAP2019.” It is working across the Group to achieve sustainable growth and improve profitability, with four priority measures: developing the foundations needed to improve management efficiency, promoting global expansion, maintaining domestic sales and increasing market share, and strengthening research and development capabilities.」
The Group continues to pursue four priority measures based on EIKEN ROAD MAP2019 and the medium-term management plan. - FY2020-Q1RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the basic strategies of the new management vision “EIKEN ROAD MAP2019.” It is working across the Group to achieve sustainable growth and improve profitability, with four priority measures: developing the foundations needed to improve management efficiency, promoting global expansion, maintaining domestic sales and increasing market share, and strengthening research and development capabilities.」
The Group continues to pursue four priority measures based on EIKEN ROAD MAP2019 and the medium-term management plan: developing its foundations, global expansion, domestic sales and research and development. - FY2019ReframedAnnual report
「Under “EIKEN ROAD MAP 2009,” the Group has achieved sustained growth by seeking to enhance corporate value and making the transformation into a global company a central focus. Believing that it was necessary to continue this growth while accelerating and expanding its businesses, the Group formulated the following basic strategies under the new “EIKEN ROAD MAP 2019” to realize its grand vision for fiscal 2028, the 90th anniversary of its founding: “As a global clinical diagnostics company, continuing to protect people’s health.”」
The framework was updated by positioning the former EIKEN ROAD MAP 2009 as the foundation for past growth and adopting the new EIKEN ROAD MAP 2019, the grand vision for fiscal 2028 and three basic strategies. - FY2019-Q3RestatedAnnual report
「Under these business conditions, the Group worked to expand sales of its core products in Japan based on the new management vision “EIKEN ROAD MAP 2009” and the medium-term management plan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue expansion of its core products in Japan, four key overseas business areas and company-wide globalization based on EIKEN ROAD MAP 2009 and the medium-term management plan. - FY2019-Q2RestatedAnnual report
「Under these business conditions, the Group worked to expand sales of its core products in Japan based on the new management vision “EIKEN ROAD MAP 2009” and the medium-term management plan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue expansion of its core products in Japan, four key overseas business areas and company-wide globalization based on EIKEN ROAD MAP 2009 and the medium-term management plan. - FY2019-Q1RestatedAnnual report
「Under these business conditions, the Group worked to expand sales of its core products in Japan based on the new management vision “EIKEN ROAD MAP 2009” and the medium-term management plan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue expansion of its core products in Japan, four key overseas business areas and company-wide globalization based on EIKEN ROAD MAP 2009 and the medium-term management plan. - FY2018RestatedAnnual report
「The Group will focus on four key product groups: reagents and analyzers for fecal occult blood testing, reagents and analyzers for urinalysis, reagents and analyzers for genetic testing using the LAMP method, and reagents for immunoserological testing, including the LZ Test. It will pursue stable growth in the Japanese market while accelerating its overseas expansion.」
The Group continues to pursue the basic policies of focusing on key business areas based on EIKEN ROAD MAP 2009, domestic growth and overseas expansion. - FY2018-Q3RestatedAnnual report
「Under these business conditions, the Group worked to expand sales of its core products in Japan based on the policies of the new management vision “EIKEN ROAD MAP 2009” and the Group medium-term management plan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue expansion of its core products in Japan, four key overseas business areas and company-wide globalization based on EIKEN ROAD MAP 2009 and the Group medium-term management plan. - FY2018-Q2RestatedAnnual report
「Under these business conditions, the Group worked to expand sales of its core products in Japan based on the policies of the new management vision “EIKEN ROAD MAP 2009” and the Group medium-term management plan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue expansion of its core products in Japan, four key overseas business areas and company-wide globalization based on EIKEN ROAD MAP 2009 and the Group medium-term management plan. - FY2018-Q1RestatedAnnual report
「Under these business conditions, the Group worked to expand sales of its core products in Japan based on the policies of the new management vision “EIKEN ROAD MAP 2009” and the Group medium-term management plan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue expansion of its core products in Japan, four key overseas business areas and company-wide globalization based on EIKEN ROAD MAP 2009 and the Group medium-term management plan. - FY2017RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the policies of the new management vision “EIKEN ROAD MAP 2009” and worked to expand sales of its core products in Japan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue a medium-term management plan based on EIKEN ROAD MAP 2009, expansion of its core products in Japan and globalization through four key overseas business areas. - FY2017-Q3RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the policies of the new management vision “EIKEN ROAD MAP 2009” and worked to expand sales of its core products in Japan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue a medium-term management plan based on EIKEN ROAD MAP 2009 and globalization through four key overseas business areas. - FY2017-Q2RestatedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the policies of the new management vision “EIKEN ROAD MAP 2009” and worked to expand sales of its core products in Japan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The Group continues to pursue a medium-term management plan based on EIKEN ROAD MAP 2009 and globalization through four key overseas business areas. - FY2017-Q1AdvancedAnnual report
「Under these business conditions, the Group formulated a medium-term management plan based on the policies of the new management vision “EIKEN ROAD MAP 2009” and worked to expand sales of its core products in Japan. In overseas markets, the Group promoted globalization by focusing on four key business areas: fecal occult blood testing, immunoserological testing, urinalysis and genetic testing.」
The document explicitly states that a Group medium-term management plan was formulated based on the new management vision, and specifies four key business areas. - FY2016First statedAnnual report
「Based on the policies of the new management vision “EIKEN ROAD MAP 2009,” we worked to expand sales of our core products in Japan while further accelerating the rollout of fecal occult blood testing reagents and analyzers overseas, expanding our gene-testing products using the LAMP method globally, strengthening our production and sales structure in China, and promoting globalization across the Group.」
This is presented as a company-wide management vision covering domestic sales, overseas expansion, the LAMP method and the China business.